Literature DB >> 6806658

Levamisole is inferior to placebo in the hyperimmunoglobulin E recurrent-infection (Job's) syndrome.

H Donabedian, D W Alling, J I Gallin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6806658     DOI： 10.1056/NEJM198207293070506

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Human hyper-IgE syndrome: singular or plural?

Authors:  Qian Zhang; Bertrand Boisson; Vivien Béziat; Anne Puel; Jean-Laurent Casanova
Journal:  Mamm Genome       Date:  2018-08-09       Impact factor: 2.957

Review 2.  Hyperimmunoglobulin E syndrome.

Authors:  M Salaria; B Poddar; V Parmar
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

3.  How antibiotics augment host defenses.

Authors:  P K Peterson
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

Review 4.  The hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

Review 5.  Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

Review 6.  The hyper-IgE syndrome.

Authors:  R H Buckley
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 10.817

Review 7.  The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency.

Authors:  Aleksandra Szczawinska-Poplonyk; Zdzislawa Kycler; Barbara Pietrucha; Edyta Heropolitanska-Pliszka; Anna Breborowicz; Karolina Gerreth
Journal:  Orphanet J Rare Dis       Date:  2011-11-15       Impact factor: 4.123

Review 8.  Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and treatment modalities.

Authors:  Hassan Hashemi; Masoumeh Mohebbi; Shiva Mehravaran; Mehdi Mazloumi; Hamidreza Jahanbani-Ardakani; Seyed-Hossein Abtahi
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.